Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor News
Share Price / Index
July 21, 2025
Not intended for U.S. and UK Media
Bayer’s Nubeqa™ (darolutamide) receives EU approval in third indication for patients with advanced prostate cancer
July 16, 2025
Far-reaching transformation advancing, delivering first signs of success:
Supervisory Board of Bayer AG extends contract of CEO Bill Anderson
July 14, 2025
Not intended for U.S. and UK Media
U.S. FDA Approves Finerenone for New Indication in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥ 40%
Discover More
